BAX326 (RIXUBIS): a novel recombinant factor IX for the control and prevention of bleeding episodes in adults and children with hemophilia B
about
Industrial production of clotting factors: Challenges of expression, and choice of host cells.2017 Clinical trials update: Innovations in hemophilia therapy.Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.Plasma-derived human factor X concentrate for on-demand and perioperative treatment in factor X-deficient patients: pharmacology, pharmacokinetics, efficacy, and safety.Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients.
P2860
BAX326 (RIXUBIS): a novel recombinant factor IX for the control and prevention of bleeding episodes in adults and children with hemophilia B
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
BAX326 (RIXUBIS): a novel reco ...... and children with hemophilia B
@ast
BAX326 (RIXUBIS): a novel reco ...... and children with hemophilia B
@en
BAX326
@nl
type
label
BAX326 (RIXUBIS): a novel reco ...... and children with hemophilia B
@ast
BAX326 (RIXUBIS): a novel reco ...... and children with hemophilia B
@en
BAX326
@nl
prefLabel
BAX326 (RIXUBIS): a novel reco ...... and children with hemophilia B
@ast
BAX326 (RIXUBIS): a novel reco ...... and children with hemophilia B
@en
BAX326
@nl
P2093
P2860
P921
P356
P1476
BAX326 (RIXUBIS): a novel reco ...... and children with hemophilia B
@en
P2093
Andrea E Hafeman
Jerzy Windyga
Maria Helena Solano Trujillo
P2860
P304
P356
10.1177/2040620714550573
P577
2014-10-01T00:00:00Z